Douglas Shemin, MD
Nephrology · Riverside, RINPI 1710934724
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,501 of the $22,407 with a category attached, or 64.7%. AstraZeneca accounts for 97.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $18,687 and has fallen 99.3% since, to $123 in 2024. Among nephrology clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 33 payments — averaging $678.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$22K
- Otsuka America Pharmaceutical, Inc.$282
- Pfizer$122
- Bayer$117
- Amgen$104
- Baxter Healthcare$19
Across 235 payments — averaging $5209.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$387K
- GSK$308K
- Akebia Therapeutics Inc$232K
- Astrazeneca UK Limited$215K
- Gilead$74K
- Novo Nordisk AS$8K
What the payments were for
- Consulting fees$14,50165%
- Speaking & faculty fees$5,45024%
- Travel & lodging$1,3126%
- Food & beverage$1,1445%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 26 | $21,762 |
| Otsuka America Pharmaceutical, Inc. | 3 | $282 |
| Pfizer | 1 | $122 |
| Bayer | 1 | $117 |
| Amgen | 1 | $104 |
| Baxter Healthcare | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,407 in reported general payments places this provider in the 90th percentile of 45 nephrology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 56 | $35,648 |
| FarxigaDapagliflozin Propanediol | 12 | $8,136 |
| KerendiaFinerenone | 12 | $7,580 |
| Potassium Citrate ErPotassium Citrate | 19 | $1,964 |
| Torsemide | 98 | $1,403 |
| Eplerenone | 13 | $1,331 |
| Losartan Potassium | 122 | $1,241 |
| Sevelamer Carbonate | 11 | $743 |
| Chlorthalidone | 18 | $528 |
| Tamsulosin Hcl | 24 | $379 |
| Allopurinol | 17 | $328 |
| Spironolactone | 35 | $270 |
| Metoprolol Succinate | 18 | $260 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $251 |
| Atorvastatin Calcium | 15 | $238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $21,762 | $8,13612 claims |
| BayerKerendia | $117 | $7,58012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 45 nephrology providers in Rhode Island.
Other nephrology in Riverside
- Reginald GohhRiverside$47K
- Ankur ShahRiverside$27K
- Jie TangRiverside$23K
- Kristen TillquistRiverside$2K
- Basma MerhiRiverside$2K
- John ObellRiverside$2K
- Sandipan ShringiRiverside$1K
- George BaylissRiverside$246
- Susie HuRiverside$205
- Matthew LynchRiverside$180
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.